Clinical Trials for VS411
VS411, ViroStatics' lead compound for the treatment of HIV/AIDS, combines the antiviral activity of didanosine (ddI) with the cytostatic propoerties of low-dose hydroxyurea (HU). The two agents, each of which have been employed in the clinical setting for many years, have been formulated together in a fixed dose combination product known as VS411. Beneficial synergies between the drugs’ mechanisms of action, combined with HU’s immunomodulating properties and the combination’s favorable resistance profile against ddI-resistant HIV, allow the investigation of lower doses of each drug than are currently prescribed, potentially minimizing the complexity, toxicity and cost of treatment while maintaining therapeutic efficacy.
If you would like additional information about any of the studies listed below, please contact:
Michael Stevens, PharmD
Chief Development Officer116 Village Boulevard Suite 200 - Princeton, NJ 08540
Phone: +1 609 951-2206 - Mobile: +1 609 213-5287
M.Stevens@ViroStatics.com
